At the present time there is general agreement that the most powerful prognostic information in patients with large bowel cancer is given by the extent of tumour spread. In general, the staging system used is that proposed by Dukes (1932) with or without the modifications suggested by Kirklin et al. (1949) and Astler and Coller (1954) . Recently a staging system has been suggested by Jass et al. (1987) which adds an assessment of peritumoral lymphocytic infiltration to the more traditional parameters of local tumour spread and lymph node status. Although Jass's system tends to increase the number of patients in whom a confident prediction of outcome may be made, this and the other systems tend to leave a large group of patients in an intermediate group, for example Dukes's stage B. While we know that patients with stage A tumours will generally do well and those with liver metastases (stage D) will tend to fare badly, the fate of those patients in the intermediate group is less certain. Other parameters have been suggested which may help to define prognosis. Histological grade has been shown to give prognostic information (Phillips et al., 1984) but tends to be subjective with wide variation in grading between observers (Blenkinsopp et al., 1981) and a tendency for the majority of tumours to be graded as moderately differentiated, reducing the discrimination of this particular parameter. Tumour cell DNA content can be rapidly and easily measured using flow cytometry either in fresh tissue (Quirke et al., 1985) or in paraffin-embedded material (Hedley et al., 1983) . It (Quirke et al., 1987; Scott et al., 1987; Goh et al., 1987; Kokal et al., 1989) . In 1985 we reported a series of 134 patients and showed that tumour cell DNA content was an independent prognostic variable in colorectal cancer (Armitage et al., 1985 (1985) and were also available for analysis.
The method of DNA staining was essentially that described by Hedley et al. (1983) . Sections of 20 gsm were cut from paraffin-embedded material, consistent with our previous report. A single block containing a representative sample of tumour was analysed. Sections were dewaxed with xylene, rehydrated through serial alcohols before being washed in water. They were disaggregated using 1 ml of 0.5% pepsin (Sigma Chemical Co., St Louis, MO, USA) in 0.9% NaCl adjusted to pH 1.5. After digestion the samples were filtered, washed and resuspended in 1 tsg ml-I 4,6-diaminido-2-phenylindole dihydrochloride (DAPI) (Boehringer Corporation, London) for 30 min at room temperature. A fuller description of this method is included in a previous publication (Armitage et al., 1985) . The tumour cell DNA content was measured using a FACS IV cell sorter (Becton Dickinson FACS Systems, Sunnyvale, CA, USA). Ultra-violet excitation was used at 350 and 360 nm and the fluorescence collected via a band pass filter at 488 nm. Between 10,000 and 50,000 cells were analysed and a histogram derived. The fluorescence intensity of each peak (channel number) was measured and the DNA index was calculated. The DNA index is the fluorescence intensity (DNA content) of the tumour cell Gl/0 peak divided by the fluorescence intensity (DNA content) of the 'normal' Gl/0 cell peak (Hiddeman et al., 1984) . Where there was no separate abnormal tumour cell peak the two peaks would coincide giving a DNA index of 1. Where there was a separate abnormal tumour cell peak (aneuploid) this was only taken to be present when it contained at least 10% of the total counted cells within this peak. Tumours were classified as tetraploid where the DNA index was between 1.9 and 2.1 and there were 15% or more of the total cells within the peak. In some aneuploid and tetraploid tumours the number of these cells as a percentage of the whole was calculated and expressed as a percentage aneuploid. The mean percentage coefficient of variance (CV) for the diploid Gl/0 peaks was 7.7 1.54 (n =47) and for the aneuploid Gl/0 peaks was 6.4 1.61 (n= 27 (Armitage et al., 1985) . Jones et al. (1988) and Jass et al. (1989) showed a correlation with tumour stage but not with histological grade. The reason for these differences is not clear. Some of these differences may be in part due to differences in methodology between series. We used 20 gm paraffin sections to be consistent with our previous work and have ourselves changed to 30 gm sections in a second, prospective series. The thicker sections will tend to give a higher proportion of aneuploid tumours. We used a single paraffin block to assess ploidy status. It is well recognised that colorectal cancers are heterogeneous with regard to ploidy (Quirke et al., 1985) and that using a single block will underestimate the number of tumours classified as aneuploid. However, Jones et al. (1988) showed that a single block will correctly classify at least 75% of tumours. If ploidy is to become a measure which is useful clinically then it may well be that it is only practical to measure ploidy in a single or limited number of blocks given the number of tumours which would require measurement. For this reason, as in our previous report, we used a single representative section.
We found that 51 % of tumours in our series were aneuploid, which is lower than most other workers who have reported 'aneuploidy rates' of between 51% and 82% (Scott et al., 1987; Hiddeman et al., 1986 ) although most of the larger series range between 51% and 65%. This lower aneuploidy rate may be due to either or both of the reasons stated above. It is interesting to note that in the series of 264 patients reported by Scott et al. (1987) a similar figure of 51% non-diploid tumours was found.
Another reason for differences in the reported series may be related to the criteria by which tumours were classified as diploid or aneuploid. We have used the criteria that 10% of cells must be within the aneuploid peak, with a DNA index between 1.1 and 1.9 and 15% between 1.9 and 2.1. This agrees with the type 3 classification proposed by Jones et al. (1988) , which classified 58% of tumours as aneuploid in their series and appeared to be the most discriminatory in terms of survival.
We found that there was overall a survival advantage to patients with diploid tumours but this was not as pronounced as previously reported by us. Although the 5-year survival of patients with DNA diploid tumours was very similar at 44%, that of patients with DNA aneuploid tumours was better in the larger series at 32% compared with 19% in our previous report. There was a greater proportion of stage C tumours and stage A tumours with a smaller proportion of stage B tumours in the larger group. Reviewing the survival curves of patients with diploid and nondiploid (aneuploid and tetraploid) tumours from various centres there is a general consistency in the survival advantage to patients with diploid tumours (Scott et al., 1987; Quirke et al., 1987; Jones et al., 1988; Jass et al., 1989) . There are a number of reports which show only a borderline or no significant relation between DNA ploidy and prognosis (Bauer et al., 1987; Schutte et al., 1987; Rognum et al., 1987) . In addition some reports show that although ploidy had prognostic significance in a univariate analysis this was lost in multivariant analysis (Jass et al., 1989) . We found that subdividing patients with non-diploid tumours into those with tetraploid and/or aneuploid did not improve discrimination. This was an agreement with the findings of Jones et al. (1988) where tetraploidy was defined in a similar way to this series and also in agreement with Jass et al. (1989) where a tetraploid peak had only to comprise of 10% of the nuclear population. Despite the survival advantage for patients with tetraploid tumours suggested by Quirke et al. (1987) we have not found evidence to support this. We failed to find prognostic value in the height of the aneuploid peak (percentage ploidy) whereas Jones et al. (1988) and Scott et al. (1987) found that the aneuploid peak size was of prognostic significance. This may be due to differences in methodology as outlined previously. It seems reasonable that more aggressive tumours would have a greater proportion of aneuploid cells or alternatively a smaller amount of stromal tissue. This inconsistency needs to be further investigated.
We have confirmed that DNA content retained its prognostic independence in the multivariant analysis in contradistinction to the report from Jass et al. (1989) . However, this may reflect the very detailed histopathological data which was available on Jass's patients which may perhaps not be available in all series. However, compared with pathological stage the contribution of DNA content is relatively small. Kokal et al. (1989) found ploidy to be the most important variable but this was in a selected group of patients who had curative survery.
Turning to subgroup analysis, we found a survival advantage in patients with diploid tumours in the following groups: stage B tumours, moderately differentiated tumours, rectal tumours and mobile tumours. This differs from other reports where it has been shown that the survival advantage was for stage C tumours (Schutte et al., 1987) . The reason for this is not clear. It would seem reasonable that if ploidy is regarded as a marker of tumour aggressiveness and potential for metastasis, that where these have already been shown, that is in stage C and D tumours, demonstration of an increased metastatic potential would add little to prognosis. Where micrometastases have not been demonstrated then one may expect a marker for such micrometastases to have prognostic significance. The observation that the prognostic value of ploidy was found in patients less than 70 years of age is less easy to explain but it is of interest that the older patients (greater than 70 years) tended to have a better survival. It may be that more older patients were excluded because they were not operated on or died postoperatively so that the 'survivors' were a selected group. We also found that ploidy had a significant influence on survival in moderately differentiated, mobile and rectal tumours. As far as moderately differentiated tumours are concerned it is not surprising that it is in this subgroup that the influence is found. Patients with poorly or well differentiated tumours are likely to have a poor or good outcome respectively and it is in the 'intermediate' group that one would expect to see an influence of a 'new' prognostic factor. As far as rectal tumours are concerned, Jass et al. (1989) and Quirke et al. (1987) studied. rectal cancers exclusively and found a significant influence of ploidy. Indeed, if preoperative knowledge of ploidy would help plan adjuvant treatment then it is in rectal cancers one would wish the maximum influence to be.
The multivariant analysis shows that stage, local extension and ploidy remained independent prognostic factors. Histological grade and surgeons' assessment of curability, factors which were highly significant in univariant analysis, lost significance. It should be remembered that surgeons' assessment of curability is mainly based on the presence or absence of distant metastases and/or local extension. The former were included in our staging system (stage D) and the latter was included separately. Thus if these factors were already taken into account, 'curability' had little further independent contribution to prognosis. This is in contrast to Jones et al. (1988) , who found that 'curability' was the most powerful prognostic variable but used Dukes's staging system without a stage D and did not include assessment of local fixity separately.
In conclusion, tumour cell DNA ploidy is an independent factor in determining patient survival after resection for colorectal cancer. It may be used in conjunction with other factors to plan and to analyse the effects of adjuvant therapy.
